ArticleTranslational cancer research2022
N6-methyladenosine methylation related immune biomarkers correlates with clinicopathological characteristics and prognosis in clear cell renal cell carcinoma.
Article in Translational cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 6 citations in OpenAlex.
- Sample-specific network analysis identifies gene co-expression patterns of immunotherapy response in clear cell renal cell carcinoma.iScience · 2025Article
- Radiogenomic correlation of hypoxia-related biomarkers in clear cell renal cell carcinoma.Journal of cancer research and clinical oncology · 2025Article
- Revealing tumor microenvironment communication through m6A single-cell analysis and elucidating immunotherapeutic potentials for cutaneous melanoma (CM).Journal of cancer research and clinical oncology · 2025Article
- RNA NNature reviews. Urology · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: m6A modification is closely related to immune response and acts critical a role in tumor progression. In this study, we attempted to evaluate the significance of m6A in immune response and explore N6-methyladenosine (m6A) methylation-related immune biomarkers in the prognosis of clear cell renal cell carcinoma (ccRCC). Methods: The RNA-seq data and clinical phenotype of ccRCC were downloaded from The Cancer Genome Atlas (TCGA) database. Immune-related genes list was downloaded from InnateDB database. Correlation analysis, survival analysis, univariate and multivariate Cox regression analysis were used to investigate the prognostic independent m6A-related immune genes, followed by prognosis risk model establishment. Patients were divided into high/low-risk groups, followed by survival analysis, clinical factors, immune checkpoint genes and gene set variation analysis in high-risk Results: Five prognostic independent m6A-related immune genes ( Conclusions: In this study, a five-gene risk model based on m6A related immune genes was developed, which showed an independent prognostic value and was associated with tumor stage, pathologic T/N/M and immune checkpoint expression in ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.